Advertisement
Organisation › Details
Inno4vac project (IMI2, EU, EFPIA 202109–202702)
The Innovative Medicines Initiative 2 (IMI2) Joint Undertaking mobilised more than € 33 million to support Inno4vac, an innovative public-private partnership to accelerate vaccine R&D timelines. It will focus on the design and application of new and highly advanced predictive models to allow a faster development and manufacturing of novel vaccines. Vaccination is one of the most impactful public health interventions in history, saving the lives of an estimated 2.5 million people every year and protecting millions more from illness and disability. Classical vaccine research and development timelines remain nevertheless long and costly, as it takes on average more than 10 years and costs more than € 800 million to bring a new vaccine to the market. Leveraging advances in technology and data science will be instrumental in providing new paths to vaccine development as the accelerated development of COVID vaccines demonstrated. Inno4vac is a new interdisciplinary project funded by the Innovative Medicines Initiative 2 (IMI2) that aims to foster health innovation by incorporating scientific and technological breakthrough from the academic and biotech sectors into industry. It is coordinated by the European Vaccine Initiative (Germany), with the support from the Sclavo Vaccines Association (Italy), for the scientific coordination, and involves 41 partners from 11 different European countries, including 37 academic institutions and SMEs, as well as GSK, Sanofi Pasteur, CureVac and Takeda as industry partners. Klaus Mauch, CEO of Insilico says: “The scientific community has recognized the urgent need to significantly reduce the time-to-market for new vaccines, as required by the continued advance of infectious diseases. Therefore, Insilico is excited to be part of the Inno4vac partnership and to work with renowned partners who will make use of Insilico's latest technology platform and modeling experience to accelerate the availability of new vaccines.” Four main areas will be addressed by Inno4vac in an integrated manner: (1) artificial intelligence will be used for in silico vaccine immune response and efficacy prediction; (2) a modular computational platform will be developed for in silico modelling of vaccine bio-manufacturing and stability testing; (3) new and improved controlled human infection models (CHIM) of influenza, Respiratory Syncytial Virus (RSV) and Clostridium difficile will be established to enable early vaccine efficacy evaluation, and (4) novel cell-based human in vitro 3D models will be developed to reliably predict immune protection. The ultimate goal of the combined effort pursued by Inno4vac is to develop more predictive biological and mathematical models of vaccine performance, and thereby to accelerate the development of new vaccines. The design of a sustainability plan will also be carried out by the project partners to ensure the long-term access to the project results, including models, beyond the duration of the Inno4vac project. As part of Inno4vac, Insilico will create and validate Digital Twins for cell cultivation to develop innovative solutions for scaling-up and controlling vaccine production in large-scale production plants together with academic and industrial partners. Quick facts about Inno4vac: Start Date: 01/09/2021 End Date: 28/02/2027 Coordinator: European Vaccine Initiative (EVI) This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101007799. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. www.imi.europa.eu *
Start | 2021-09-01 start | |
Group | Innovative Health Initiative (IHI JU) | |
Industry | vaccine technology | |
Industry 2 | drug development | |
City | n. a. | |
Address record changed: 2021-11-14 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Insilico Biotechnology AG. (8/24/21). "Press Release: Insilico Biotechnology AG Participates in Inno4vac, a European new public-private partnership to innovate vaccine development". Stuttgart. | ||
Record changed: 2023-07-15 |
Advertisement
More documents for Innovative Health Initiative (IHI JU)
- [1] Thermosome GmbH. (6/20/23). "Press Release: Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment". Munich....
- [2] Insilico Biotechnology AG. (8/24/21). "Press Release: Insilico Biotechnology AG Participates in Inno4vac, a European new public-private partnership to innovate vaccine development". Stuttgart....
- [3] Exscientia Ltd.. (8/18/20). "Press Release: Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats". Brussels....
- [4] Boehringer Ingelheim. (6/8/20). "Press Release: New Consortium EUbOPEN Will Provide Tools to Unlock Disease Biology. 66 Million Euros to Generate Open-access Chemical Tools". Frankfurt & Ingelheim....
- [5] Innovative Medicines Initiative (IMI). (5/12/20). "Press Release: IMI Announces COVID Projects, Boosts Funding Pot to EUR 72 million". Brussels....
- [6] MLM Medical Labs GmbH. (4/15/19). "Press Release: Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline Project to Enable Development and Implementation of Novel Safety Biomarkers". Mönchengladbach....
- [7] bioMérieux S.A.. (4/1/19). "Press Release: University of Antwerp, bioMérieux, and Wellcome Trust to Coordinate VALUE-Dx, a European Public-Private Partnership to Fight Antimicrobial Resistance through Diagnostics". Antwerp, London & Marcy l’Eoile....
- [8] Innovative Medicines Initiative (IMI). (1/22/19). "Press Release: Open Access Drug Development Tools Feature in New IMI Call for Proposals". Brussels....
- [9] Agena Bioscience, Inc.. (7/24/18). "Press Release: Agena Announces MassARRAY Technology Selected for Participation in CANCER-ID Consortium". San Diego, CA....
- [10] Innovative Medicines Initiative (IMI). (7/18/18). "Press Release: New Antimicrobial Resistance Accelerator Programme Part of Latest IMI Calls for Proposals". Brussels....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top